News Marizyme, Inc.

Equities

GBSX

US5703721028

Delayed OTC Markets Other stock markets 16:16:35 03/05/2024 BST			5-day change	1st Jan Change
0.072 ^USD	-24.21%		+72.41%	-28.07%

02-06	Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	CI
2023	Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™	04-16	GL
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	02-06	CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Marizyme CEO Delivers Business Update	23/10/23	EQ
Marizyme CEO Delivers Business Update	23/10/23	GL
OTC Active Stocks Watchlist (EPAZ, MRZM, GCEI, TMGI)	09/10/23	AQ
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™	06/10/23	GL
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft	06/10/23	CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23	CI
MARIZYME, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	24/05/23	AQ
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Marizyme, Inc. announced a financing transaction	14/05/23	CI
MARIZYME INC : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	10/05/23	AQ
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products	10/05/23	GL
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products	10/05/23	AQ
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products	10/05/23	CI
Marizyme, Inc. announced that it has received $0.265216 million in funding	09/05/23	CI
Marizyme CEO Delivers Business Update	03/05/23	GL
MARIZYME INC Submission of Matters to a Vote of Security Holders (form 8-K/A)	26/04/23	AQ
MARIZYME INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	20/04/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Marizyme, Inc.

Equities

GBSX

US5703721028

Summary

Filters